INTRODUCTION
Spontaneous and catheter-related thromboembolic events are infrequent but serious complications of patients in neonatal intensive care units (NICU). Infants most commonly affected are those with symptoms associated with arterial catheters including diminished pulses, poor capillary refill of the involved extremity, hypertension, cardiac failure and gangrene.
A number of perinatal risk factors for thrombosis have been identified including systemic infections, dehydration, congenital heart disease, asphyxia, polycythemia, intravascular catheters, inherited thrombophilias (e.g. protein C, protein S and antithrombin III deficiency) and transplacental passage of maternal antiphospholipid and anticardiolipin antibodies. 1 Maternal diabetes forms the most frequently identified risk factor but the mechanism(s) for this increased risk of thrombosis is largely unknown. 1 Oppenheimer and Esterly 2 showed that the risk of thrombosis in infants of diabetic mothers (IDM) was 15.8% compared with <1% in the non-IDM group. In a retrospective analysis of patients admitted to our NICUs from 1995 to 1999, umbilical artery catheter-associated symptomatic arterial thrombosis was 10 times more frequent in IDMs than non-IDMs (p<0.0001) (unpublished) .
Previous studies have focused on specific biochemical prothrombotic markers in IDMs. Coagulation studies including prothrombin time, activated partial thromboplastin time, fibrinogen, fibrin split products, platelet count, inhibitors of fibrinolysis -antiplasmin, alpha-2-macroglobulin and alpha-1-antitrypsin have been measured in IDMs and controls. [3] [4] [5] In vitro abnormalities in the platelet-vascular arachidonic acid metabolism and increased retraction of fibrin clots in umbilical veins of IDM have also been demonstrated. [6] [7] [8] 9 We hypothesized that the pathophysiology of thrombosis in IDMs is multifactorial and likely involves interactions among genetic and acquired factors affecting the procoagulant, anticoagulant and fibrinolytic pathways. The objective of the study was to compare the prevalence of common prothrombotic risk factors in cord blood in a cohort of IDMs to a matched control group.
METHODS

Study Design
This was a prospective case-control cohort study carried out in women delivering at Hartford Hospital. The hospital averages approximately 4000 births annually and serves an inner city and suburban population. The patients were enrolled from July 2001 to December 2001. The Hartford Hospital IRB approved the study and informed verbal consent was obtained from the mothers by one of the investigators.
Study Population
Study population included all infants Z36 weeks of gestation born to mothers with gestational diet controlled diabetes (A1-DM) or insulin-dependent both gestational and type I diabetes (ID-DM) diagnosed according to accepted criteria (ACOG). The control group (Controls) was comprised of healthy infants Z36 weeks' gestation born to mothers with normal pregnancy and no medical problems. The study and control groups were matched for mode of delivery. Mothers with pregnancy-induced or chronic hypertension, liver, kidney, heart or metabolic disease were excluded, as were those on heparin or with a history of anticardiolopin/antiphospholipid antibodies or thrombophilias. Neonates with a congenital anomaly or intrauterine growth restriction were excluded.
Cord Blood Collection
Blood was collected from the umbilical vein (18 to 20 ml) either from the cord before the delivery of the placenta and/or from the placenta using a 20-gauge needle and a vacutainer. The blood was then sent immediately to the laboratory where it was processed.
Clinical Information
Pertinent clinical information including maternal age, ethnicity and parity and neonatal gestational age, sex, birth weight, APGAR scores and neonatal intensive care admissions was also obtained.
Cord Blood Assays
Cord blood was tested for MTHFR, FVL, P20210A, PC activity, Lp(a), PAI(1), FVIII and C-peptide levels, a measure of acute glycemic control during labor. MTHFR, FVL and P20210A were analyzed by DNA amplication. The enzyme digestion of PCR product was carried out and the bands were visualized on a polyacrilamide gel after electrophoresis. 10 Lp(a) and PAI (1) were measured by ELISA using peroxide conjugated Lp(a) antibodies and mouse monoclonal anti-PAI(1) antibodies, respectively [American Diagnostica]. PC activity was measured by chromogenic method, FVIII activity by clotting method and C-peptide by immunochemiluminometric assay (ICMA) [Esoterix] .
Statistical Analysis
Outcomes to be compared included FVL, P20210A, MTHFR, FVIII, PC, Lp(a) and PAI-1 levels. Differences in continuously distributed outcomes between the total IDM study group and the control group of infants of nondiabetic mothers (non-IDMs) were evaluated using t-tests. Analysis of variance and multiple comparisons tests were used to compare infants in the diabetic subgroups, such as diet-controlled (A1-IDM) /insulin-dependent maternal diabetes (ID-IDM) and the non-IDMs (C). Nonparametric analogues, such as the Mann-Whitney and Kruskal-Wallis tests, were used as needed. Differences in nominal variables or meaningful categorizations of continuous outcomes were analyzed using w 11,12 A p-value <0.05 was considered statistically significant.
RESULTS
The maternal cohort consisted of 17 A1-DM, 19 ID-DM and 20 C mothers. There was one set of twins born to an ID-IDM mother resulting in 20 ID-IDM. Diabetic mothers vs Control mothers were similar in age, ethnicity, parity and mode of delivery. The IDM vs Control infants were similar in gestational age, sex, birth weight and APGAR scores. There was no difference in the minutes to collection of cord blood after birth [IDM: 5.1±2.7 vs C: 6.0±3.9] (NS). No infant had a clinically apparent thrombotic event and there was no difference in NICU admissions IDM vs Controls (8 vs 10%). IDMs had a higher prevalence of hypoglycemia compared to Controls (30 vs 0%; p ¼ 0.005) but all cases resolved with early initiation of feeds, not requiring admission to the NICU. There was no significant difference in C-peptide values between IDM (1.20±0.8 ng/ml) and Controls (0.97±0.50 ng/ml) suggesting good short-term antenatal glycemic control in the diabetic mothers.
There were no significant differences in the prevalence of FVL, P20210A, MTHFR mutations, FVIII and PAI-1 levels as shown in Table 1 . Two neonates in the A1-IDM group (11.8%) had an Lp(a) level greater than 100 mg/dl (contributing to the large standard deviation in the total IDM group), vs none in the control or ID-IDM groups. Among all IDMs, 40% had elevated Lp(a) >50 mg/dl, (45% among ID-IDMs, 35% among A1-IDMs) compared to 20% of the Control infants, but this difference was not statistically significant. The PC activity was significantly decreased in the IDM group compared to controls, 0.35±0.12 vs 0.44±0.9 U/ml (p<0.005). However, this difference was due to depressed PC levels in the A1-IDM group (30%) compared to both ID-IDM (38%) (p ¼ 0.05) and Controls (44%) (p ¼ 0.001) (Figure 1 ).
SIGNIFICANCE
Coagulation is a delicately balanced system usually allowing neither spontaneous bleeding nor thrombus formation in vivo. Thromboses are prevented in vivo by the inhibitors of coagulation and the fibrinolytic system. 1 Although the composition of the neonatal coagulation and fibrinolytic system is similar to older children and adults, the concentrations of various individual procoagulants, anticoagulant and fibrinolytic factors are markedly different. For healthy neonates, these differences are physiologic and do not result in clinical bleeding or thromboses. However, sick neonates are at an increased risk for bleeding and thromboses.
This study demonstrates that infants born to a population of well-controlled diabetic women have lower PC activity compared to controls. This difference was more pronounced in the A1-IDM group. No differences in the common genetic mutations (FVL, P20210A and MTHFR), FVIII levels or PAI-1 levels were found. In addition, a trend towards higher Lp(a) levels in IDMs (including two infants with Lp(a) values >100 mg/dl in the A1-IDM group) was found, although this did not reach statistical significance. Thus, the increased risk of spontaneous or catheter-related thrombosis IDMs could be explained at least in part by a deficiency in the anticoagulant (PC) and possibly in the fibrinolytic (Lp(a)) pathways.
There is limited previous study of biochemical prothrombotic markers in IDMs. Easa and Coen 5 measured postnatal hematocrits, prothrombin and partial thromboplastin times, Factors V, VIII, X, XII, platelet count, Von Willebrand's factor, antithrombin III and thrombin degradation products in a group of 17 IDMs compared to controls. The IDM group had minimally depressed platelet counts and elevated antithrombin III levels; however, the clinical course of half of the IDMs was complicated by either maternal pre-eclampsia or respiratory distress syndrome potentially confounding the results. Mildly depressed platelet counts were also noted in a retrospective review of infants born to insulin-treated mothers. 3 Manco-Johnson et al. 13 studied cord blood PC levels in high-risk newborns and noted critically low values in two of 17 IDMs who were found to have clinically significant thrombosis. However, in contrast to the present study, no difference in mean PC levels between IDMs and controls was detected. This difference may be accounted for by the larger sample size in our study. Further, no differentiation of diabetic subgroups was mentioned in the earlier study. In contrast to these earlier studies, the majority of IDMs in the current study were otherwise well and patients with complications of pregnancy known to alter coagulation (pre-eclampsia, chronic hypertension, etc.) were excluded. Hence, the lower cord blood PC levels more likely reflect the influence of maternal diabetes on neonatal coagulation.
PC, a vitamin K-dependent zymogen synthesized in the liver, inhibits coagulation by inactivating factors VIIIa and Va. 14 Inherited forms of PC deficiency lead to spontaneous thromboses and complete deficiency is associated with purpura fulminans. Acquired forms of PC deficiency have been noted in adults with sepsis, inflammation, protein losing enteropathy and type I diabetes and preterm critically ill newborns. 15, 16 The presumed mechanism involves a low-grade activation of the coagulation system resulting in the consumption of coagulation factors including PC. 3 The explanation for the association between maternal diabetes and lower PC levels in cord blood is unclear, although there is evidence that the diabetic state in pregnancy may inappropriately activate the coagulation system. Bellart et al. 17 studied the changes in coagulation and fibrinolysis in diabetic women during pregnancy, delivery and 3 days post partum and found that thrombinantithrombin III complexes, a clinical marker of thrombin generation, were increased and postulated that diabetes itself may induce activation of the coagulation system.
Infants in the A1-IDM group had lower PC levels than both the ID-IDM and C groups. This suggests that metabolic control may have been better in the women treated with insulin rather than diet alone, although not reflected in differences in C-peptide levels. Maternal hemoglobin A1C levels, a marker of more long-term metabolic control, although not part of this study protocol, were measured prenatally and showed no significant differences. Adult studies have noted a correlation between PC levels and metabolic control in nonpregnant type I diabetes mellitus with the lowest PC levels found in patients with the poorest metabolic control. 18 They also found that the ratio of PC to factor II (prothrombin) was significantly decreased in diabetic population vs controls suggesting that the mechanism for decreased PC levels was more likely increased clearance than decreased synthesis. 18 Certain limitations of the current study should be considered. All assays were performed using cord blood. Abnormalities found using cord blood might be secondary to activation of coagulation during delivery, although one would expect this to occur similarly in both IDMs and controls. Consistent with this was the finding of low FVIII activity levels in all groups compared to usual neonatal values. The IDMs in this study may not be representative of the general diabetic obstetric population since the diabetic women in this study appeared to have excellent control as demonstrated by normal birth weight, minimal newborn complications and normal cord C-peptide levels. However, it is likely that differences between IDMs and controls would be magnified in poorly controlled women. Lp(a) levels were elevated in the IDM groups but this difference did not reach statistical significance (p ¼ 0.08). There is no normative data on Lp(a) levels in cord blood, so that sample size calculation was based on expected PC values. It is possible that a larger sample size might have resulted in significant Lp(a) level difference between C and IDM groups. This finding may be of importance since the adult literature suggests that there is an association between elevated Lp(a) levels and macrovascular disease in noninsulin-dependent diabetic population, although no such relationship has been found in insulin-dependent diabetic population. 19 Further, Lp(a), an LDL-based lipid particle, is potentially thrombogenic because it inhibits the conversion of plasminogen to plasmin preventing fibrinolysis. 19 In summary, IDMs have lower concentrations of PC in their cord blood compared to controls. This may be one explanation for their increased risk of thromboembolic events. Larger studies, especially in less well-controlled diabetic mothers, are needed to confirm this relationship.
